PatientsVille.com Logo

PatientsVille

Delursan Side Effects

Common Delursan Side Effects


The most commonly reported Delursan side effects (click to view or check a box to report):

Renal Failure Acute (3)
Cytolytic Hepatitis (3)
Gamma-glutamyltransferase Increased (2)
Haematuria (2)
Arthralgia (2)
Hepatic Encephalopathy (2)
Cutaneous Vasculitis (2)
Hepatic Enzyme Increased (2)
Soft Tissue Disorder (2)
Synovitis (2)
Oedema Peripheral (2)
Anaemia (1)
Anaemia Macrocytic (1)
Angiotensin Converting Enzyme Increased (1)
Amenorrhoea (1)
Abdominal Tenderness (1)
Small Intestinal Haemorrhage (1)
Constipation (1)
Abnormal Behaviour (1)
Alanine Aminotransferase Increased (1)

➢ More



If you or someone in your family has experienced a serious side effect to a health product, you are encouraged to report the experience to your health care professional (e.g. physician, pharmacist). You could also complete a copy of the side effect reporting form or report your side effect to FDA.

Side effects reports are analyzed to discover potential health product safety signals. Some important reactions may take an extremely long time to develop or occur infrequently. Continued monitoring of adverse reactions is thus essential to maintain a comprehensive safety and effectiveness profile of health products.

Delursan Side Effects Reported to FDA

The following Delursan reports list potential signals of serious risks and new safety information that were identified using the FDA Adverse Event Reporting System (FAERS).
FAERS is a database that contains information on adverse event and medication errors reports submitted to FDA by healthcare professionals (such as physicians, pharmacists, nurses and others), consumers (such as patients, family members, layers and others) and manufacturers.


The appearance of Delursan on this list does not mean that FDA has concluded that the drug has the listed risk. It means that FDA has identified a potential safety issue, but it does not mean that FDA has found a causal relationship between the drug and the listed risk.
Toxic Epidermal Necrolysis, Bladder Disorder, Haematuria, Graft Versus Host Disease In Intestine, Renal Failure Acute, Hepatitis Fulminant, Oedema
This is a report of a 41-year-old female patient (weight: NA) from FR, suffering from the following symptoms/conditions: NA, who was treated with Delursan (ursodeoxycholic Acid) Tablet (dosage: 3 Df, Bid, Oral, start time: Jun 05, 2013), combined with:
  • Fortum (1 Df, Qid, Intravenous)
  • Flagyl
  • Gentamicine
  • Ambisome
  • Bactrim (2 Df, 3x/weekly, Itravenous)
  • Noxafil
  • Cancidas
  • Folinic Acid (50mg, 3x/wk, Intravenous)
and developed a serious reaction and side effect(s). The consumer presented with:
  • Toxic Epidermal Necrolysis
  • Bladder Disorder
  • Haematuria
  • Graft Versus Host Disease In Intestine
  • Renal Failure Acute
  • Hepatitis Fulminant
  • Oedema
which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Delursan (ursodeoxycholic Acid) Tablet treatment in female patients, resulting in toxic epidermal necrolysis side effect. The patient was hospitalized.

Abnormal Behaviour, Rash Pruritic, Dry Skin, Miliaria, Transient Global Amnesia, Skin Lesion
This report suggests a potential Delursan Abnormal Behaviour, Rash Pruritic, Dry Skin, Miliaria, Transient Global Amnesia, Skin Lesion side effect(s) that can have serious consequences. A 63-year-old female patient (weight: NA) from FR was diagnosed with the following symptoms/conditions: biliary cirrhosis and used Delursan (dosage: NA) starting 201303. Soon after starting Delursan the patient began experiencing various side effects, including:
  • Abnormal Behaviour
  • Rash Pruritic
  • Dry Skin
  • Miliaria
  • Transient Global Amnesia
  • Skin Lesion
Drugs used concurrently: NA. Although Delursan demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as abnormal behaviour, may still occur.

Rash Maculo-papular, Burning Sensation, Eczema, Eosinophilia, Leukocytosis, Hypoalbuminaemia, Oedema Peripheral
This Rash Maculo-papular, Burning Sensation, Eczema, Eosinophilia, Leukocytosis, Hypoalbuminaemia, Oedema Peripheral problem was reported by a health professional from FR. A 57-year-old female patient (weight: NA) was diagnosed with the following symptoms/conditions: liver disorder,jaundice. On Jul 17, 2012 this consumer started treatment with Delursan (ursodeoxycholic Acid) Tablet (dosage: NA). The following drugs were being taken at the same time: NA. When commencing Delursan (ursodeoxycholic Acid) Tablet, the patient experienced the following unwanted symptoms/side effects:
  • Rash Maculo-papular
  • Burning Sensation
  • Eczema
  • Eosinophilia
  • Leukocytosis
  • Hypoalbuminaemia
  • Oedema Peripheral
The patient was hospitalized.Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as rash maculo-papular, may become evident only after a product is in use by the general population.

Pancreatic Cyst, Weight Decreased, Hepatic Steatosis
This is a report of a 50-year-old male patient (weight: NA) from FR. The patient developed the following symptoms/conditions: hepatic fibrosis and was treated with Delursan (dosage: 5 Df, Qd, Oral) starting 201107. Concurrently used drugs:
  • Kenzen
Soon after that, the consumer experienced the following side effects:
  • Pancreatic Cyst
  • Weight Decreased
  • Hepatic Steatosis
This opens a possibility that Delursan treatment could cause the above reactions, including pancreatic cyst, and some male subjects may be more susceptible.


Porphyria Non-acute
A 48-year-old female patient (weight: NA) from FRANCE with the following symptoms/conditions: NA started Delursan treatment (dosage: NA) on Jan 01, 2007. Soon after starting Delursan treatment, the subject experienced various side effects, including:
  • Porphyria Non-acute
Concurrently used drugs:
  • Folic Acid
  • Copegus
  • Boceprevir
  • Pegasys
  • Betaselen
This finding indicates that some female patients could be more vulnerable to Delursan.

Synovitis, Soft Tissue Disorder, Arthralgia
A 55-year-old female patient from FRANCE (weight: NA) experienced symptoms, such as: cholangitis and was treated with Delursan(dosage: NA). The treatment was initiated on Feb 09, 2012. After that a consumer reported the following side effect(s):
  • Synovitis
  • Soft Tissue Disorder
  • Arthralgia
Concurrently used drugs, which potentially could have contributed to side effect(s) or affected Delursan efficacy:
  • Irbesartan
  • Propranolol
  • Zoledronoc Acid (Unk Ukn, Unk)
  • Vitamin D
  • Calcium Carbonate


Synovitis, Arthralgia, Soft Tissue Disorder
In this report, Delursan was administered for the following condition: cholangitis.A 55-year-old female consumer from FRANCE (weight: NA) started Delursan treatment (dosage: NA) on Feb 09, 2012.Sometime after starting the treatment, the patient complained of the following side effect(s):
  • Synovitis
  • Arthralgia
  • Soft Tissue Disorder
A possible interaction with other drugs could have contributed to this reaction:
  • Calcium Carbonate
  • Zoledronoc Acid (Unk Ukn, Unk)
  • Propranolol
  • Irbesartan
  • Vitamin D
Establishing a causal relationship between a specific drug and consumer's side effects is complex, but it is possible that in this report Delursan treatment could be related to the listed above side effect(s).

Cytolytic Hepatitis
This is a report of the following Delursan side effect(s):
  • Cytolytic Hepatitis
A female patient from FRANCE (weight: NA) presented with the following condition: NA and received a treatment with Delursan (dosage: 500 Mg, Bid) starting: Feb 03, 2011.The following concurrently used drugs could have generated interactions:
  • Cyclophosphamide (490 Mg, Qd)
  • Thymoglobulin (225 Mg, Qd)
  • Polaramine (10 Mg, Unk)
  • Solu-medrol (20 Mg, Tid)
  • Thymoglobulin (147.5 Mg, Once)
  • Thymoglobulin (3.5 Mg/kg, Qd)
  • Fludarabine Phosphate (49 Mg, Qd)
  • Sodium Bicarbonate (100 Ml, Qid)
This report suggests that a Delursan treatment could be associated with the listed above side effect(s).

Cytolytic Hepatitis
This Delursan report was submitted by a 58-year-old male consumer from FRANCE (weight: NA). The patient was diagnosed with: NA and Delursan was administered (dosage: NA) starting: Oct 06, 2011. The consumer developed a set of symptoms:
  • Cytolytic Hepatitis
Other drugs used simultaneously:
  • Busulfan
  • Valium
  • Fludara
  • Pantoprazole
  • Fludara
  • Solu-medrol
  • Multi-vitamins
  • Zofran
Those unexpected symptoms could be linked to a Delursan treatment, however establishing a potential drug-safety problem requires a more detailed clinical analysis.

Cytolytic Hepatitis
This is a report of a possible correlation between Delursan use and the following symptoms/side effect(s):
  • Cytolytic Hepatitis
which could contribute to an assessment of Delursan risk profile.A female consumer from FRANCE (weight: NA) was suffering from NA and was treated with Delursan (dosage: 500 Mg, Bid) starting Feb 03, 2011.Other concurrent medications:
  • Solu-medrol (20 Mg, Tid)
  • Thymoglobulin (147.5 Mg, Once)
  • Polaramine (10 Mg, Unk)
  • Fludarabine Phosphate (49 Mg, Qd)
  • Thymoglobulin (3.5 Mg/kg, Qd)
  • Cyclophosphamide (490 Mg, Qd)
  • Sodium Bicarbonate (100 Ml, Qid)


Hypoglycaemia, Coma
A 53-year-old female patient from FRANCE (weight: NA) presented with the following symptoms: NA and after a treatment with Delursan (dosage: NA) experienced the following side effect(s):
  • Hypoglycaemia
  • Coma
The treatment was started on NS. Delursan was used in combination with the following drugs:
  • Voltaren
  • Aldalix
  • Aspirin
  • Stablon
  • Noctamid
  • Panos
  • Propranolol (160 Mg, 1x/day)
  • Atarax
The patient was hospitalized.This report could alert potential Delursan consumers.

Liver Transplant Rejection
In this report, a male patient from FRANCE (weight: NA) was affected by a possible Delursan side effect.The patient was diagnosed with cholestasis,hypertension. After a treatment with Delursan (dosage: NA, start date: Mar 10, 2010), the patient experienced the following side effect(s):
  • Liver Transplant Rejection
The following simultaneously used drugs could have led to this reaction:
  • Flodil Lp
  • Cyclosporine
  • Bipreterax
  • Neoral
  • Ribavirin
  • Cellcept
  • Peginterferon Alfa-2a
The findings here stress that side effects should be taken into consideration when evaluating a Delursan treatment.

Cholestasis, Antimitochondrial Antibody Positive, Portal Hypertension, Biliary Cirrhosis Primary, Treatment Failure, Disease Progression
This is a report of a 70-year-old female patient from FRANCE (weight: NA), who used Delursan (ursodeoxycholic Acid) Tablet (dosage: 500 Mg, Bid, Oral) for a treatment of biliary cirrhosis primary. After starting a treatment on Jan 01, 1989, the patient experienced the following side effect(s):
  • Cholestasis
  • Antimitochondrial Antibody Positive
  • Portal Hypertension
  • Biliary Cirrhosis Primary
  • Treatment Failure
  • Disease Progression
The following drugs could possibly have interacted with the Delursan (ursodeoxycholic Acid) Tablet treatment NA.Taken together, these observations suggest that a Delursan (ursodeoxycholic Acid) Tablet treatment could be related to side effect(s), such as Cholestasis, Antimitochondrial Antibody Positive, Portal Hypertension, Biliary Cirrhosis Primary, Treatment Failure, Disease Progression.

Toxic Skin Eruption
This toxic skin eruption side effect was reported by a consumer or non-health professional from FRANCE. A 80-year-old female patient (weight:NA) experienced the following symptoms/conditions: NA. The patient was prescribed Delursan (ursodeoxychloic Acid) 250mg Tablet (dosage: 250 Mg Tid Oral), which was started on Jan 01, 2004. Concurrently used drugs:
  • Mysoline (250mg Bid Oral)
  • Hept A Myl (heptaminol) Tablet (187.8mg Qid Oral)
  • Stresam (etifoxine Hydrochloride)
  • Vastarel (trimetazidine) Tablet (35mg Bid Oral)
  • Calcium Carbonate
  • Fosavance (alendronic Acid, Colecalciferol)
When starting to take Delursan (ursodeoxychloic Acid) 250mg Tablet the consumer reported the following symptoms:
  • Toxic Skin Eruption
The patient was hospitalized. These side effects may potentially be related to Delursan (ursodeoxychloic Acid) 250mg Tablet.

Transient Ischaemic Attack
This is a Delursan Tablets 250mg (ursodesoxycholic Acid) side effect report of a 47-year-old male patient (weight:NA) from FRANCE, suffering from the following symptoms/conditions: NA, who was treated with Delursan Tablets 250mg (ursodesoxycholic Acid) (dosage:250 Mg Oral, start time: Jan 01, 2000), combined with:
  • Xagrid (anagrelide) (2 Mg (0.5 Mg 4 Times A Day) Oral)
  • Previscan (fluindione) (15 Mg Oral)
  • Nexium (Oral)
  • Avlocardyl L.p. Prolonged Release Capsule (160 Mg Oral)
  • Acetaminophen (Oral)
  • Tardyferon (folic Acid) (Twice A Day Oral)
, and developed a serious reaction and a transient ischaemic attack side effect. The patient presented with:
  • Transient Ischaemic Attack
which developed after the beginning of treatment. The patient was hospitalized. This side effect report can indicate a possible existence of increased vulnerability to Delursan Tablets 250mg (ursodesoxycholic Acid) treatment in male patients suffering from NA, resulting in transient ischaemic attack.

Alanine Aminotransferase Increased, Anaemia Macrocytic, Anti-hbs Antibody Positive, Aspartate Aminotransferase Increased, C-reactive Protein Increased, Coagulation Factor Decreased, Gamma-glutamyltransferase Increased, Hepatic Enzyme Increased, Inflammation
This report suggests a potential Delursan (ursodesoxycholic Acid) alanine aminotransferase increased side effect(s) that can have serious consequences. A 20-year-old female patient from FRANCE (weight:NA) was diagnosed with the following health condition(s): cholestasis,pain,autoimmune hepatitis and used Delursan (ursodesoxycholic Acid) (dosage: 500 Mg) starting NS. Soon after starting Delursan (ursodesoxycholic Acid) the patient began experiencing various side effects, including:
  • Alanine Aminotransferase Increased
  • Anaemia Macrocytic
  • Anti-hbs Antibody Positive
  • Aspartate Aminotransferase Increased
  • C-reactive Protein Increased
  • Coagulation Factor Decreased
  • Gamma-glutamyltransferase Increased
  • Hepatic Enzyme Increased
  • Inflammation
Drugs used concurrently:
  • Augmentin '125'
  • Imurel (25 Mg)
  • Neoral (50 Mg)
The patient was hospitalized. Although Delursan (ursodesoxycholic Acid) demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as alanine aminotransferase increased, may still occur.

Amenorrhoea, Angiotensin Converting Enzyme Increased, Blood Alkaline Phosphatase Increased, Blood Creatinine Decreased, Disseminated Intravascular Coagulation, Gamma-glutamyltransferase Increased, Haemoglobin Decreased, Hepatosplenomegaly, Hyperproteinaemia
This amenorrhoea problem was reported by a consumer or non-health professional from FRANCE. A 56-year-old female patient (weight: NA) was diagnosed with the following medical condition(s): cholestasis.On Nov 13, 2007 a consumer started treatment with Delursan (ursodeoxycholic Acid) (dosage: 500 Mg (delursan) Oral). The following drugs/medications were being taken at the same time: NA. When commencing Delursan (ursodeoxycholic Acid), the patient experienced the following unwanted symptoms /side effects:
  • Amenorrhoea
  • Angiotensin Converting Enzyme Increased
  • Blood Alkaline Phosphatase Increased
  • Blood Creatinine Decreased
  • Disseminated Intravascular Coagulation
  • Gamma-glutamyltransferase Increased
  • Haemoglobin Decreased
  • Hepatosplenomegaly
  • Hyperproteinaemia
The patient was hospitalized. Although all drugs are carefully tested before they are licensed for use, they carry potential side effect risks. Some side effects, such as amenorrhoea, may become evident only after a product is in use by the general population.

Haematuria, Thrombocytopenia
This is a Delursan (ursodeoxycholic Acid) side effect report of a 85-year-old female patient (weight: NA) from FRANCE. The patient developed the following symptoms/conditions: NA and was treated with Delursan (ursodeoxycholic Acid) (dosage: NA) starting Jan 01, 2007. Concurrently used drugs:
  • Pantoprazole Sodium (Po)
  • Stablon (tianeptine) Tablets 12.5 Mg (1 Df, 2 Days Po)
  • Actonel
  • Calcidose (calcium Carbonate)
  • Potassium Chloride
  • Furosemide
  • Solupred (prednisolone)
  • Amiodarone Hcl
Soon after that, the consumer experienced the following of symptoms:
  • Haematuria
  • Thrombocytopenia
The patient was hospitalized. This opens a possibility that Delursan (ursodeoxycholic Acid) could cause haematuria and that some female patients may be more susceptible.

Asthenia, Hepatic Enzyme Increased, Pruritus
A 48-year-old female patient (weight: NA) from FRANCE with the following symptoms: NA started Delursan (ursodeoxycholic Acid) 250 Mg treatment (dosage: Oral) on Oct 14, 2007. Soon after starting Delursan (ursodeoxycholic Acid) 250 Mg treatment, the consumer experienced several side effects, including:
  • Asthenia
  • Hepatic Enzyme Increased
  • Pruritus
. Concurrently used drugs:
  • Meteospasymol (alverine Citrate 60 Mg, Simethicone 300 Mg)
  • Spasfon (phloroglucinol, Trimethylphloroglucinol)
The patient was hospitalized. This finding indicates that some patients can be more vulnerable to developing Delursan (ursodeoxycholic Acid) 250 Mg side effects, such as asthenia.

Abdominal Tenderness, Anaemia, Constipation, Faecaloma, Flatulence, Pallor, Peritoneal Effusion, Renal Failure Acute, Small Intestinal Haemorrhage
This abdominal tenderness side effect was reported by a consumer or non-health professional from FRANCE. A 88-year-old female patient (weight:NA) experienced the following symptoms/conditions: cholelithiasis,atrial fibrillation.The patient was prescribed Delursan (ursodeoxycholic Acid) (dosage: 250 Mg; Oral), which was started on NS. Concurrently used drugs:
  • Previscan (fluindione) (Oral)
  • Cordarone (Oral)
  • Deroxat (paroxetine) (Oral)
  • Folic Acid (Oral)
  • Omeprazole (Oral)
  • Primaxin (Oral)
.When starting to take Delursan (ursodeoxycholic Acid) the consumer reported symptoms, such as:
  • Abdominal Tenderness
  • Anaemia
  • Constipation
  • Faecaloma
  • Flatulence
  • Pallor
  • Peritoneal Effusion
  • Renal Failure Acute
  • Small Intestinal Haemorrhage
These side effects may potentially be related to Delursan (ursodeoxycholic Acid). The patient was hospitalized.

Lung Infection Pseudomonal, Oedema Peripheral, Pancytopenia, Pneumonia, Rash, Renal Failure Acute
This is a report of a 47-year-old male patient (weight: NA) from FRANCE, suffering from the following symptoms/conditions: NA, who was treated with Delursan (ursodeoxycholic Acid) (dosage: 500 Mg Oral, start time: Nov 16, 2006), combined with:
  • Allopurinol (100 Mg Oral)
  • Certican (everolimus) (1.5 Mg Oral)
  • Cyclosporine (150 Mg Oral)
  • Aspegic (dl-lysine Acetylsalicylate) (100 Mg Oral)
  • Imuran (100 Mg Oral)
and developed a serious reaction and side effect(s). The consumer presented with:
  • Lung Infection Pseudomonal
  • Oedema Peripheral
  • Pancytopenia
  • Pneumonia
  • Rash
  • Renal Failure Acute
which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Delursan (ursodeoxycholic Acid) treatment in male patients, resulting in lung infection pseudomonal side effect. The patient was hospitalized.

Hepatic Pain, Jaundice, Transaminases Increased
This report suggests a potential Delursan (ursodesoxycholic Acid) Hepatic Pain, Jaundice, Transaminases Increased side effect(s) that can have serious consequences. A 14-year-old male patient (weight: NA) from FRANCE was diagnosed with the following symptoms/conditions: hepatic pain,transaminases increased,leukaemia and used Delursan (ursodesoxycholic Acid) (dosage: 500 Mg Tablets Po) starting NS. Soon after starting Delursan (ursodesoxycholic Acid) the patient began experiencing various side effects, including:
  • Hepatic Pain
  • Jaundice
  • Transaminases Increased
Drugs used concurrently: NA.The patient was hospitalized. Although Delursan (ursodesoxycholic Acid) demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as hepatic pain, may still occur.

Optic Neuritis, Scotoma, Visual Acuity Reduced
This Optic Neuritis, Scotoma, Visual Acuity Reduced problem was reported by a consumer or non-health professional from FRANCE. A 51-year-old male patient (weight: NA) was diagnosed with the following symptoms/conditions: cholangitis,spondyloarthropathy. On Feb 24, 2005 this consumer started treatment with Delursan (ursodesoxycholic Acid) (dosage: 1 G Film-coated Tablets Po). The following drugs were being taken at the same time:
  • Methotrexate (10 Mg Po)
  • Remicade (400 Mg Iv)
  • Speciafoldine (folic Acid)
  • Cortan
  • Contramal Lp (tramadol Hydrochloride)
  • Acetaminophen
  • Forlax (macrogol)
  • Lansoprazole
When commencing Delursan (ursodesoxycholic Acid), the patient experienced the following unwanted symptoms/side effects:
  • Optic Neuritis
  • Scotoma
  • Visual Acuity Reduced
The patient was hospitalized.Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as optic neuritis, may become evident only after a product is in use by the general population.

Cutaneous Vasculitis, Hepatic Encephalopathy
This is a report of a 62-year-old female patient (weight: NA) from . The patient developed the following symptoms/conditions: biliary cirrhosis primary and was treated with Delursan (dosage: NA) starting Aug 18, 2005. Concurrently used drugs:
  • Lasilix
  • Captopril
  • Lopressor
  • Previscan
  • Sintrom
  • Nph Insulin (Dose: 20 Units On The Morning And 14 Units In The Evening.)
  • Lantus
  • Actrapid (Dose: 4 Units On The Morning And 4units On The Evening.)
Soon after that, the consumer experienced the following side effects:
  • Cutaneous Vasculitis
  • Hepatic Encephalopathy
The patient was hospitalized. This opens a possibility that Delursan treatment could cause the above reactions, including cutaneous vasculitis, and some female subjects may be more susceptible.

Cutaneous Vasculitis, Hepatic Encephalopathy
A 62-year-old female patient (weight: NA) from FRANCE with the following symptoms/conditions: biliary cirrhosis primary started Delursan (ursodesoxycholic Acid) treatment (dosage: Po) on NS. Soon after starting Delursan (ursodesoxycholic Acid) treatment, the subject experienced various side effects, including:
  • Cutaneous Vasculitis
  • Hepatic Encephalopathy
Concurrently used drugs:
  • Insulin
  • Beta-carotene And Bilberry (difrarel)
  • Duphalac
The patient was hospitalized. This finding indicates that some female patients could be more vulnerable to Delursan (ursodesoxycholic Acid).



Keep Track of Side Effects

Note Your Observations

It is really important to keep of your symptoms, right from the time you start a new medicine. You can do it any way you prefer: in a notebook, in a computer file or using our online tool. You should also note down any other medicines you are taking at the same time, because there could be an interaction between these medicines.

Why Your Notes are Important

Your notes could be helpful in several ways:

  • You can use them to remind you of details that may alert your health care professional(s) to a problem
  • You will have a record to refer to in the future, in case you are ever prescribed the same medicine again

  • Log Form

    You can use the following log form to write down important information, like the date and time you experienced a side effect and your symptoms, how strong the symptoms were, and any other medicines you were using.

    Medicine Name and Dosage:
    Side Effects Scale Date & Time Other Medicine(s) or Treatment(s)
    Scale: 1 = very mild to 10 = very bad

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


    Discuss Delursan Side Effects

    Did You Have a Delursan Side Effect?

    Yes, Severe
    Yes, Moderate
    Yes, Minor
    No

    How Effective is Delursan for You?

    Exceeded Expectations
    Effective
    Somewhat Effective
    Not Effective

    Delursan Safety Alerts, Active Ingredients, Usage Information

    More About Delursan

    Side Effects reported to FDA: 25

    Delursan safety alerts: No

    Reported deaths: 1

    Reported hospitalizations: 5

    Latest Delursan clinical trials

    Delursan Reviews

    No reviews, be a first to report a side effect via side effect reporting form